drugset / Trial / NCT02266966

Effect of F2695 on Brain Activity Measured by Functional Magnetic Resonance Imaging

NCT02266966

Phase 1 Completed 17 enrolled Pierre Fabre Laboratories
RandomizedCrossoverQuadruple-blindTreatment

Summary

The aim of this functional Magnetic Resonance Imaging (MRI) study is to assess the effect of single dose of F2695 at 75mg on modulation of the cerebral motor network.

Timeline

Start
2014-04
Primary completion
2014-09
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Levomilnacipran Small molecule 75 mg

Indications

No indication recorded.